Triple-negative breast cancer: high T-bet-expressing TILs predict better survival

  • Breast Cancer Res Treat

  • curated by Miriam Davis, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Tumor-infiltrating lymphocytes (TILs) expressing the transcription factor T-bet, a master regulator, positively predict longer recurrence-free survival (RFS) and OS compared with T-bet-negative TILs in patients with triple-negative breast cancer (TNBC).

Why this matters

  • T-bet expression may be a new prognostic biomarker for TNBC that will help guide choice of adjuvant chemotherapy and development of new therapies.

Study design

  • Retrospective cohort of 242 women with TNBC who underwent surgery without neoadjuvant chemotherapy.
  • T-bet+ and CD8+ expression on TILs, assayed by immunohistochemical staining, was each defined as ≥30 cells/6.25×10-3 mm2.
  • Funding: Fukuoka Foundation for Sound Health Cancer Research Fund.

Key results

  • 27.7% of tumors were T-bet+ and 52.5% were CD8+.
  • T-bet expression and CD8 expression were correlated (P<.0001>
  • Median follow-up of patients was 67 (range, 2-150) months.
  • Compared with patients with T-bet− tumors, those with T-bet+ tumors had longer OS (P=.047).
  • Compared with patients with CD8+/T-bet− tumors, the combination of CD8+ and T-bet+ tumors was associated with better RFS (P=.037) and OS (P=.024).
  • Adjuvant chemotherapy was more beneficial for patients with T-bet+ tumors (RFS: P=.031; OS: P=.0003).
  • According to multivariate analysis, T-bet expression on TILs was an independent and positive prognostic marker (RFS: HR, 0.36; P=.037; OS: HR, 0.30; P=.039).

Limitations

  • Retrospective observational design.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit